NASDAQ:AKBA Akebia Therapeutics Q4 2023 Earnings Report $3.86 -0.02 (-0.52%) Closing price 04:00 PM EasternExtended Trading$3.87 +0.01 (+0.26%) As of 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Akebia Therapeutics EPS ResultsActual EPS-$0.04Consensus EPS -$0.04Beat/MissMet ExpectationsOne Year Ago EPS-$0.04Akebia Therapeutics Revenue ResultsActual Revenue$56.20 millionExpected Revenue$55.64 millionBeat/MissBeat by +$560.00 thousandYoY Revenue GrowthN/AAkebia Therapeutics Announcement DetailsQuarterQ4 2023Date3/14/2024TimeQ4 2023 Earnings ReleaseConference Call DateThursday, March 14, 2024Conference Call Time4:00PM ETUpcoming EarningsAkebia Therapeutics' Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Akebia Therapeutics Earnings HeadlinesAkebia Therapeutics (NASDAQ:AKBA) Hits New 1-Year High - What's Next?July 13, 2025 | americanbankingnews.comAkebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual ConferenceJuly 8, 2025 | globenewswire.comMissed the Run So Far? This Is Your Second ChanceAccording to history, the final stretch of the crypto cycle is here — and this short window is where fortunes are made. Inside The Crypto Code Workshop, two experts reveal how to get positioned early, lock in profits, and access their top altcoin picks before the crowd. All attendees receive $10 in free Bitcoin just for showing up.July 18 at 2:00 AM | Crypto Swap Profits (Ad)Leerink Partners Reiterates a Buy Rating on Akebia Therapeutics (AKBA) With a $7 PTJuly 7, 2025 | msn.comAkebia Therapeutics, Inc. (AKBA) - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comAkebia Therapeutics, Inc. (AKBA) Shareholders Greenlight 18.9 Million Share IncreaseJuly 2, 2025 | insidermonkey.comSee More Akebia Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Akebia Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Akebia Therapeutics and other key companies, straight to your email. Email Address About Akebia TherapeuticsAkebia Therapeutics (NASDAQ:AKBA) (NASDAQ: AKBA) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for patients with kidney disease. The company’s primary research and development efforts center on treating anemia associated with chronic kidney disease (CKD) through the discovery of oral small-molecule inhibitors of hypoxia-inducible factor prolyl hydroxylase (HIF-PH). Akebia’s lead product candidate, vadadustat, is designed to stimulate erythropoiesis by stabilizing HIF, potentially offering an alternative to injectable therapies for anemia in dialysis and non-dialysis CKD patients. Akebia has established strategic partnerships to advance its pipeline globally, most notably with Otsuka Pharmaceutical Co., Ltd., which holds co‐development and commercialization rights for vadadustat in select markets. Through these collaborations, Akebia seeks to leverage its scientific expertise and partner resources to conduct late-stage clinical trials, obtain regulatory approvals, and build a commercial infrastructure. The company also explores additional HIF-PH inhibitors and combination therapies aimed at improving outcomes in nephrology. Founded in 2007 and headquartered in Cambridge, Massachusetts, Akebia went public in December 2014 to accelerate its research and development programs. Since its inception, the company has expanded its operations across North America, with research collaborations and clinical trial sites in Europe and Asia. Akebia’s management team comprises industry veterans in nephrology, drug development and regulatory affairs, guiding the company through clinical milestones and toward its goal of transforming care for kidney disease patients.Written by Jeffrey Neal JohnsonView Akebia Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your PortfolioCitigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings Report Upcoming Earnings NXP Semiconductors (7/21/2025)Verizon Communications (7/21/2025)Comcast (7/22/2025)Intuitive Surgical (7/22/2025)Texas Instruments (7/22/2025)Chubb (7/22/2025)Canadian National Railway (7/22/2025)Capital One Financial (7/22/2025)Danaher (7/22/2025)General Motors (7/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
